Dose of 5.0 x 10^9 CFU (Cohort 1) + Dose of 7.5 x 10^9 CFU (Cohort 2) + Dose of 1.1 x 10^10 CFU (Cohort 3) + Dose of of 1.7 x 10^10 CFU (Cohort 4)
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Typhoid
Conditions
Typhoid
Trial Timeline
May 1, 2008 → Dec 1, 2008
NCT ID
NCT00679172About Dose of 5.0 x 10^9 CFU (Cohort 1) + Dose of 7.5 x 10^9 CFU (Cohort 2) + Dose of 1.1 x 10^10 CFU (Cohort 3) + Dose of of 1.7 x 10^10 CFU (Cohort 4)
Dose of 5.0 x 10^9 CFU (Cohort 1) + Dose of 7.5 x 10^9 CFU (Cohort 2) + Dose of 1.1 x 10^10 CFU (Cohort 3) + Dose of of 1.7 x 10^10 CFU (Cohort 4) is a phase 2 stage product being developed by Emergent BioSolutions for Typhoid. The current trial status is completed. This product is registered under clinical trial identifier NCT00679172. Target conditions include Typhoid.
What happened to similar drugs?
0 of 1 similar drugs in Typhoid were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00679172 | Phase 2 | Completed |
Competing Products
7 competing products in Typhoid
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Purified Vi capsular polysaccharide of Salmonella typhi conjugated to tetanus toxoid as carrier protein (Typhoid Vi Conjugate Vaccine I.P.). Trade name: ZyVac® TCV | Zydus Lifesciences | Phase 3 | 47 |
| Vi-CRM197 vaccine + Vi Polysaccharide (PS) vaccine + Pneumococcal conjugate vaccine | Novartis | Phase 2 | 35 |
| NVGH Vi-CRM197 12.5 mcg + NVGH Vi-CRM197 5.0 mcg + NVGH Vi-CRM197 1.25 mcg + Vi-polysaccharide vaccine | Novartis | Phase 2 | 35 |
| Typherix + NVGH Vi-CRM197 | Novartis | Phase 1 | 29 |
| NVGH Vi-CRM197 | Novartis | Phase 2 | 35 |
| Vi-CRM197 vaccine + Pneumococcal conjugate vaccine + Vi Polysaccharide (PS) vaccine | Novartis | Phase 2 | 35 |
| Vivotif | Bavarian Nordic | Pre-clinical | 23 |